Compare ALM & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | COGT |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2016 | 2018 |
| Metric | ALM | COGT |
|---|---|---|
| Price | $13.89 | $31.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $22.33 | ★ $36.21 |
| AVG Volume (30 Days) | ★ 5.9M | 1.5M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $817.94 | N/A |
| Revenue Next Year | $158.05 | $1,733.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.24 | $11.61 |
| 52 Week High | $24.41 | $43.73 |
| Indicator | ALM | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 31.56 |
| Support Level | $12.47 | $30.90 |
| Resistance Level | $14.92 | $37.69 |
| Average True Range (ATR) | 1.19 | 1.25 |
| MACD | -0.58 | -0.16 |
| Stochastic Oscillator | 8.55 | 9.59 |
Almonty Industries Inc is engaged in the development of the Sangdong Mine in South Korea, and the Company is currently mining, processing, and shipping tungsten concentrate from the Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal (Panasqueira Mine). Additionally, the Company is evaluating its molybdenum project with inferred mineral resources on a separate property adjacent to the tungsten orebody at the Sangdong Mine, its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora (Valtreixal Mine), and the newly-acquired Gentung Browns Lake tungsten project located in Montana, USA (Gentung-Browns Lake Project). The company has two geographical locations: the Iberian Peninsula (Spain and Portugal) and the Republic of Korea.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.